In the hyperlipidemia combination drug market of 'statin + ezetimibe', competition to develop a two-drug combination using 'low-dose statin' is intensifying. According to the pharmaceutical industry on the 11th, Yuhan Corporation is developing a combination drug for hyperlipidemia with Ezetimibe added to Atorvastatin 5mg through its subsidiary Addpharma. Yuhan already has three products, including Atovamibe, a two-component complex. The dose of Ezetimibe is the same at 10 mg, and only the doses of Atorvastatin are different at 10 mg, 20 mg, and 40 mg. Yuhan Corporation's plan is to add a combination drug based on the 5mg dose of Atorvastatin.


According to the original developer, Addpharma, the develo